Esmo 2021 – colorectal cancer could be Mirati’s golden ticket
Adagrasib looks better than Amgen’s Lumakras, which could explain why Mirati has been dragging its heels in lung cancer.
Esmo 2021 – Mirati bids to be belle of the ball
At a conference largely focused on big biopharma a few biotech catalysts stand out.
Mirati fiddles as its share price burns
Speedy US approval for Amgen’s Lumakras was an embarrassment for Mirati, which has gone quiet as its share price has drifted downwards.
Biotech’s important upcoming data
Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.
Asco 2021 movers – PDS wins, but big pharma reigns
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
Amgen’s low-dose Kras curveball
The company reveals that it will test a low dose of sotorasib, a move apparently requested by the US FDA.
